Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing.

Vaccines (Basel)

Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore.

Published: December 2024

Although the Coronavirus disease 2019 (COVID-19) pandemic has ended, there are still many important lessons we can learn, as the pandemic profoundly affected every area of laboratory practice. During the pandemic, extensive changes to laboratory staffing had to be implemented, as many healthcare institutions required regular screening of all healthcare staff. Several studies examined the effectiveness of different screening regimens and concluded that repeated testing, even with lower sensitivity tests, could rival the performance of gold-standard RT-PCR testing in the detection of new cases. Many assay evaluations were performed both in the earlier and later periods of the pandemic. They included both nucleocapsid/spike antibodies and automated antigen assays. Early in the pandemic, it was generally agreed that the initial nucleocapsid antibody assays had poor sensitivity when used before 14 days of disease onset, with total or IgG antibodies being preferred over the use of IgM. Spike antibody assays gradually replaced nucleocapsid antibody assays, as most people were vaccinated. Spike antibodies tracked the rise in antibodies after vaccination with mRNA vaccines and became invaluable in the assessment of vaccine response. Studies demonstrated robust antibody secretion with each vaccine dose and could last for several months post-vaccination. When antigen testing was introduced, they became effective tools to identify affected patients when used serially or in an orthogonal fashion with RT-PCR testing. Despite the numerous findings during the pandemic period, research in COVID-19 has slowed. To this day it is difficult to identify a true neutralizing antibody test for the virus. An appropriate antibody level that would confer protective immunity against the plethora of new variants remains elusive. We hope that a summary of events during the pandemic could provide important insights to consider in planning for the next viral pandemic.

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines13010009DOI Listing

Publication Analysis

Top Keywords

antibody assays
12
pandemic
8
rt-pcr testing
8
nucleocapsid antibody
8
antibody
6
testing
5
reflections covid-19
4
covid-19 literature
4
literature review
4
review sars-cov-2
4

Similar Publications

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study.

Dermatol Ther (Heidelb)

January 2025

Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.

Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.

View Article and Find Full Text PDF

Testing for myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG) is essential to the diagnosis of MOG antibody-associated disease (MOGAD). Due to its central role in the evaluation of suspected inflammatory demyelinating disease, the last 5 years has been marked by an abundance of research into MOG-IgG testing ranging from appropriate patient selection, to assay performance, to utility of serum titers as well as cerebrospinal fluid (CSF) testing. In this review, we synthesize current knowledge pertaining to the "who, what, where, when, why, and how" of MOG-IgG testing, with the aim of facilitating accurate MOGAD diagnosis in clinical practice.

View Article and Find Full Text PDF

Domestic Dogs Exposed to Orthopoxvirus in Urban Areas of Brazil.

Viruses

January 2025

Laboratório de Vírus, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, Belo Horizonte 31270-901, Brazil.

Domestic animals can share viral pathogens with humans, acting mainly as a bridge host. The genus hosts important zoonotic species that have emerged in urban areas worldwide. Nevertheless, the role of companion animals, such as dogs and cats, in the circulation of orthopoxviruses in urban areas remains poorly understood.

View Article and Find Full Text PDF

Self-assembling ferritin nanoparticle technology is a widely used vaccine development platform for enhancing the efficacy of subunit vaccines by displaying multiple antigens on nanocages. The dengue virus (DENV) envelope domain III (EDIII) protein, the most promising antigen for DENV, has been applied in vaccine development, and it is essential to evaluate the relative immunogenicity of the EDIII protein and EDIII-conjugated ferritin to show the efficiency of the ferritin delivery system compared with EDIII. In this study, we optimized the conditions for the expression of the EDIII protein in , protein purification, and refolding, and these optimization techniques were applied for the purification of EDIII ferritin nanoparticles.

View Article and Find Full Text PDF

This study aimed to create a new recombinant virus by modifying the EV-A71 capsid protein, serving as a useful tool and model for studying human Enteroviruses. We developed a new screening method using EV-A71 pseudovirus particles to systematically identify suitable insertion sites and tag types in the VP1 capsid protein. The pseudovirus's infectivity and replication can be assessed by measuring postinfection luciferase signals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!